SML3399

CHZ868

≥98% (HPLC)

• Sinónimos: CHZ 868, CHZ-868, N-(4-((2-((2,4-Difluorophenyl)amino)-1,4-dimethyl-1H-benzo[d]imidazol-5-yl)oxy)pyridin-2-yl)acetamide, N-[4-[[2-[(2,4-Difluorophenyl)amino]-1,4-dimethyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]acetamide, NVP-CHZ 868, NVP-CHZ-868, NVP-CHZ868
• Fórmula empírica (notación de Hill): C₂₂H₁₉F₂N₅O₂
• Número CAS: 1895895-38-1
• Peso molecular: 423.42
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD30533612
• Assay: ≥98% (HPLC)
• Form: powder

Propiedades

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to pink
• solubility: DMSO: 2 mg/mL, clear (Warmed)
• storage temp.: 2-8°C

Descripción

Biochem/physiol Actions

Orally active, type II tyrosine kinase I inhibitor against VEGFR1/2 (FLT1/KDR), PDGFR1/2, KIT, and ROS1 oncogenic fusions/mutations-drivent growth.

CHZ868 is a type II tyrosine kinase inhibitor that exhibits potent antiproliferation activity against VEGFR1/2 (FLT1/KDR), PDGFR1/2, KIT, and ROS1 TEL fusions-, as well as JAK2 V617F, but not RAF V600E, mutation-driven oncogenic growth (IC50 = 2/11, 4/23, 16, 40, 51 against respective BaF3 transformants) via stablizing target kinases in the inactive “DFG-out” conformation. CHZ868 overcomes Type I JAK inhibitor resistance of JAK2/MPN mutant MPN and JAK2 I682F/CRLF2-rearranged B-ALL cells both in cultures and in mice in vivo (30-40 mg/kg/day p.o.). Comparing to BBT594, CHZ868 is ineffective against BCR-ABL, TEL-FLT3, TEL-RET.

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable